Feasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than 60 Years

Table 1: Patients and Transplant Characteristics

	N°	%

SEX Male/Female	14/16

AGE at BMT, years Median (Range) > 65 yrs	63 (60-70)	43
AGE at BMT, years Median (Range) > 65 yrs	13/30	43

HIGH RISK at Diagnosis	30/30	100

STATUS at BMT CR REL/RES	18/30	60
STATUS at BMT CR REL/RES	12/30	40

HCT-CI ≤ 2 ≥ 3	12/30	40
HCT-CI ≤ 2 ≥ 3	18/30	60

DONOR SIBLING UNRELATED	18/30	60
DONOR SIBLING UNRELATED	12/30	30

PREPARATIVE REGIMENS Tyotepa-cyclophosphamide ± ATG Busulfan-cyclophosphamide ± ATG Fludarabine-based RIC	14/30	46
	4/30	14
	12/30	40

RIC	26/30	87

SOURCE OF Progenitor cells PBSC BM	19/30	63
SOURCE OF Progenitor cells PBSC BM	11/30	37

Median CD34+ cells within the graft x 10⁶ (range)	5
Median CD34+ cells within the graft x 10⁶ (range)	(0.8-18.5)

CR, Complete Remission; REL, Relapsed Leukemia; RES, Resistant Leukemia. BM, bone marrow; PBSC peripheral blood stem cells; RIC, reduced intensity conditioning.